President, Chief Executive Officer and Director Director/Executive Officer Since: 2023 Age: 57 Committee Service: None Professional Experience: President and Chief Executive Officer , Vir Biotechnology, Inc. (2023 Present) Executive Committee, and Executive Vice President and Global Head of Strategy, Business Development & Licensing, Pharmaceuticals Division, Bayer AG (2019 2023) Various positions of increasing responsibility, including Vice President of M&A Operations and Divestitures for the Pharmaceuticals Group and Head of Infectious Diseases & Vaccines Business Development, Johnson & Johnson (1991 2019) Additional experience leading commercial business unit in Europe, as well as drug discovery research in both Europe and the United States Education: M.Sc., Molecular Biology, Vrije Universiteit Brussel M.Sc., Engineering and Biochemistry, Ghent University Ph.D., Biotechnology, Ghent University MBA, Erasmus University Rotterdam Other Public Company Boards: Arrowhead Pharmaceuticals Inc. (2019 2023) Kronos Bio, Inc. (2021 2023) Other Affiliations: Emerging Companies Section Governing Board, Biotechnology Innovation Organization (BIO) Board of Directors, Gladstone Foundation (non-profit) The Nominating and Corporate Governance Committee and Board believe Dr. De Backer is qualified to serve on the Board due to her extensive scientific training, business acumen, significant knowledge and experience in the biotechnology, healthcare and pharmaceutical industries and the perspective and experience she brings to the role of Vir Bio s Chief Executive Officer.